TrialCurveAML18 (CPX-351 vs DA + gemtuzumab ozogamicin): reconstructed Kaplan–Meier curves
CPX-351 vs daunorubicin, cytarabine, and gemtuzumab ozogamicin in older adults with non-adverse-risk AML: the NCRI AML18 trial. Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | Blood. 2025 Nov 18;147(10):1048–57. doi: 10.1182/blood.2025031006 |
|---|---|
| DOI | 10.1182/blood.2025031006 |
| Registry | NCT02272478 |
| Phase | Phase 2, Phase 3 |
| Conditions | Acute Myeloid Leukaemia, Myelodysplastic Syndrome |
| Interventions | Arm A Mylotarg plus DA Versus CPX-351, Arm B Vosaroxin and Decitabine, Arm D Small molecule or Not, Arm C DA V FLAG-Ida V DAC, Arm E CPX-351 (200 V 300), Arm F DA V IDAC |
| Sponsor | Cardiff University |
| Enrolment | 1600 |
| Source licence | Figure published under CC BY 4.0 |
Event free survival — AML18 randomization, CPX-351 vs DAGO2/DA
From figure panel A · validated against the values printed on the figure · curve source: vision model
Reconstructed from the published curve. Median: CPX-351 11.4 months; DAGO2/DA 17.9 months. Survival at 12 months: CPX-351 46%; DAGO2/DA 67%. Hazard ratio DAGO2/DA vs CPX-351 0.72 (95% CI 0.56–0.92).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| CPX-351 | 295 | 208 | 11.4 |
| DAGO2/DA | 144 | 89 | 17.9 |
- DAGO2/DA vs CPX-351: reconstructed HR 0.72 (95% CI 0.56–0.92)
Landmark survival (reconstructed)
| Time | CPX-351 | DAGO2/DA |
|---|---|---|
| 6 mo | 69.8% | 80.5% |
| 12 mo | 46.3% | 67.1% |
| 18 mo | 36.2% | 49.6% |
| 24 mo | 30.4% | 40.1% |
Checks against the published figure
- CPX-351 events: printed 208, reconstructed 208 pass
- CPX-351 n: printed 295, reconstructed 295 pass
- DAGO2/DA events: printed 89, reconstructed 89 pass
- DAGO2/DA n: printed 144, reconstructed 144 pass
- hazard ratio (direction inferred): printed 0.73, reconstructed 0.719 pass
Overall survival — AML18 randomization, CPX-351 vs DAGO2/DA
From figure panel B · validated against the values printed on the figure · curve source: vision model
Reconstructed from the published curve. Median: CPX-351 22.4 months; DAGO2/DA not reached. Survival at 12 months: CPX-351 68%; DAGO2/DA 79%. Hazard ratio DAGO2/DA vs CPX-351 0.61 (95% CI 0.46–0.82).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| CPX-351 | 295 | 170 | 22.4 |
| DAGO2/DA | 144 | 60 | not reached |
- DAGO2/DA vs CPX-351: reconstructed HR 0.61 (95% CI 0.46–0.82)
Landmark survival (reconstructed)
| Time | CPX-351 | DAGO2/DA |
|---|---|---|
| 6 mo | 80.9% | 89.5% |
| 12 mo | 67.7% | 78.8% |
| 18 mo | 57.2% | 69.7% |
| 24 mo | 47.1% | 63.0% |
Checks against the published figure
- CPX-351 events: printed 170, reconstructed 170 pass
- CPX-351 n: printed 295, reconstructed 295 pass
- DAGO2/DA events: printed 60, reconstructed 60 pass
- DAGO2/DA n: printed 144, reconstructed 144 pass
- hazard ratio (direction inferred): printed 0.62, reconstructed 0.612 pass
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Load these data in R or Python
# R
library(survival)
d <- read.csv("https://trialcurve.com/data/trials/aml18-cpx-351-vs-da-plus-gemtuzumab-ozogamicin-1.csv")
survfit(Surv(time, event) ~ arm, data = d)
coxph(Surv(time, event) ~ arm, data = d)
# Python
import pandas as pd
from lifelines import KaplanMeierFitter
d = pd.read_csv("https://trialcurve.com/data/trials/aml18-cpx-351-vs-da-plus-gemtuzumab-ozogamicin-1.csv")
for arm, g in d.groupby("arm"):
KaplanMeierFitter().fit(g.time, g.event, label=arm).plot_survival_function()
Suggested citation: Blood. 2025 Nov 18;147(10):1048–57. doi: 10.1182/blood.2025031006 doi:10.1182/blood.2025031006. Reconstructed data: TrialCurve (2026), https://trialcurve.com/trials/aml18-cpx-351-vs-da-plus-gemtuzumab-ozogamicin
Report a problem with these data
Related trials
- AGILE (long-term follow-up): Overall survival
- Acalabrutinib vs chlorambucil + rituximab in CLL (Asian phase 3): BICR-assessed duration of response; BICR-assessed progression-free survival; Overall survi
- ADMYRE: Overall survival; Progression-free survival with PD confirmation by investigator's assessm
- CEPHEUS: Overall survival; Progression-free survival
- CLL12: Event-free survival (EFS); Overall survival (OS)
- CLL14 (5-year update): Overall survival; Progression-free survival
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials